What if your spouse were a borderline Type 2 diabetic? If you had the money, you could hire someone to follow her or him around the clock, sort of like a glorified personal trainer. Your spouse would make sure he or she took a daily mile-long walk, did some weight training to build muscle mass and would stop you from eating ice cream or cake or drinking a glass of wine. Read More
WEST BLOOMFIELD, Michigan & SALEM, N.H. – (Nov. 3, 2016 ) Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imaging system. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This proven imaging modality will help improve cancer detection in women who are at greater risk of developing breast cancer. Read More
NEW YORK, NY–(Marketwired – Oct 6, 2016) – Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More
NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare.
Psilos, a prominent digital health venture and growth stage investment firm, says digital therapeutics improves health outcomes by addressing chronic conditions through behavioral changes, before they become worse. The new generation of digital therapeutics is demonstrating clinical efficacy by marrying the latest developments in behavioral economics, smartphones, game-ification, biometric sensors, data analytics and artificial intelligence. The long-term goal of digital therapeutics is to bend the healthcare cost curve. Read More
NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annualOUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More
Finalists are named in the RWJF’s Mood Challenge for ResearchKit, and Psilos says the digital therapeutics market will soar in popularity in the next 5 years.
Psilos Group Chief Executive Stephen Krupa has taken the same position at portfolio company HealthEdge Software Inc., a provider of software technology to about 30 health plans. Read More
SALEM, N.H.–(BUSINESS WIRE)–A breakthrough retrospective study in AJR’s August issue confirmed Gamma Medica’s molecular breast imaging (MBI) technology’s high incremental cancer detection rate of 7.7 cancers per thousand (7.7/1000) and overall clinical effectiveness as a secondary screening tool in finding 13 malignancies among 1,696 women with dense breast tissue following mammograms that read negative for cancer.1 Read More
The objective of the HealthMine Digital Health Report is
to give health plan sponsors (payers and employers) insight into
the adoption and impact of digital health tools.
Consumer use of digital health tools is growing rapidly. According
to research firm Accenture, using digital health tools in primary
care could save the US healthcare system $10 billion annually. As
the aging population and prevalence of chronic disease in America
grows, internet-connected health devices and applications can
help support primary and specialty healthcare. Read More
SALEM, N.H.–(BUSINESS WIRE)–Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Dr. Nathalie Johnson, M.D., FACS, of the Legacy Cancer Institute and the Legacy Breast Health Centers in Portland, Oregon has agreed to join the organizations’ clinical advisory board, currently comprised of distinguished clinicians and thought leaders with expertise in women’s health technologies and diagnostic imaging. Dr. Johnson and the board will provide strategic and clinical advice as Gamma Medica continues commercialization and enhancements of its LumaGEM® Molecular Breast Imaging system. Read More
SALEM, NH – May 5, 2016 – Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density. Today, about half of all women in the United States have dense breast tissue, making them four to five times more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime. Read More
Digital healthcare, a discipline with enormous potential to dramatically improve healthcare and healthcare delivery as we know it, is no longer an experiment or a novelty. It is a budding industry attracting not only major new players and consumers but, most important, investors – the key to ongoing adoption and growth. Read More
EL PASO, TX and SALEM, NH – March 28, 2016 – Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Southwest X-Ray, the leading outpatient services provider in El Paso, TX, has installed Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in its Gateway Blvd. West location. Southwest X-Ray will utilize the LumaGEM MBI system as a secondary diagnostic tool for inconclusive mammography screenings in patients with dense breast tissue. Read More
An emerging, ground-breaking trend, the convergence of the healthcare system with digital technology, is rippling across healthcare and providing compelling investment opportunities for astute investors, particularly in private markets. Best of all, it’s only in its early stages. Read More
Expanding the reach of Molecular Breast Imaging; a new standard of care in early breast cancer detection
WILLOUGHBY, OH and SALEM, NH – January 6, 2016 – Alpha Imaging, one of the largest independent sales and service providers of advanced medical imaging equipment, today announced that it has executed a distribution agreement with Gamma Medica, Inc. The agreement covers distribution of Gamma Medica’s LumaGEM Molecular Breast Imaging solution in the Midwest and Mid-Atlantic regions. Read More
As 2015 winds down, it’s a good time to look into the crystal ball for one of the toughest industries to predict: healthcare.
We recently picked the brain of David Eichler, a managing partner with New York-based venture capital firm Psilos Group. Eichler (pictured) focuses on investments in digital health and medical device companies, and he currently is the board chair of Gamma Medica and Caregiver Services. Read More
Pink is the new black this October, which marks the 30th anniversary of National Breast Cancer Awareness Month. NFL players are clad in bright pink shoes and wrist bands. American Airlines employees are wearing pink uniform accents and serving complimentary pink lemonade. Police departments across the country are patrolling in pink cruisers. It’s all for a great cause. The money and awareness raised through this campaign helps to fight an insidious disease that will kill more than 40,000 women in the U.S. this year. Read More
Women throughout Wisconsin will now have access to a new standard of care in early breast cancer detection
MARSHFIELD, WI and SALEM, NH – October 27, 2015 – Marshfield Clinic Health System (MCHS) and Gamma Medica, Inc., today announced their partnership to install the LumaGEM® Molecular Breast Imaging (MBI) system on a new mobile medical unit, creating the world’s first mobile MBI service. Read More
SALEM, N.H, – October 12, 2015 – Gamma Medica, Inc., a breast imaging medical device company, today announced the CE Mark approval allowing for the sale and distribution of the LumaGEM® Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA. Read More
Norwest Venture Partners General Partner Robert Mittendorff, MD, and Breaking Health Host Steve Krupa of Psilos Group bring their considerable experiences to bear. Krupa delves into Mittendorff’s ability to balance practicing medicine with identifying game-changing new digital health technologies for one of the leading investors in digital health. Mittendorff also discusses the highlights he sees in the coming Digital Healthcare Innovation Summit including Digital Therapeutics, Population Health, and the Rise of the Consumer. Read More
Innovators Needed to Address the Most Sweeping Changes in Healthcare in 50 Years, Say Digital Healthcare VC Firm Psilos Group and HealthCare Media Group, Healthegy Read More
The cost-sharing part of CMS’s upcoming Medicare Advantage Value-Based Insurance Design Model will allow insurers to provide some healthcare services at no cost or reduced costs to patients, and hospitals to provide needed care to targeted populations.
Salem, N.H., June 8, 2015 – Gamma Medica, a leader in molecular breast imaging (MBI) technology, announced today that Philip M. Croxford has been appointed as Chief Executive Officer. The Company also named Scott Headland as its new Vice President of Sales. These executive changes align with Gamma Medica’s focus on commercializing its unique breast imaging technology for improved cancer detection in the 40 percent of women with dense breast tissue. Gamma Medica’s former CEO, Jim Calandra, has left the company to pursue other business opportunities. Read More